ADIPOQ and COVID-19: These results indicate that COVID‐19 may independently reduce adiponectin in those with respiratory failure, and if true, this holds specific implications for patients with hypoadiponectinemia at baseline (e.g., obesity, type 2 diabetes mellitus, etc.).